Letter by Vos et al Regarding Article, "Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials"

被引：4
|
作者：
Vos, Eddie
Rose, Colin P. [1 ]
Biron, Pierre [2 ]
机构：
[1] McGill Univ, Dept Med, Montreal, PQ, Canada
[2] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada
来源：
CIRCULATION | 2010年 / 122卷 / 23期
关键词：
NITRIC-OXIDE;
D O I：
10.1161/CIRCULATIONAHA.110.954016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E576 / E576
页数：1
相关论文
共 17 条
  • [1] Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials
    Mora, Samia
    Glynn, Robert J.
    Hsia, Judith
    MacFadyen, Jean G.
    Genest, Jacques
    Ridker, Paul M.
    CIRCULATION, 2010, 121 (09) : 1069 - 1077
  • [2] Letter by Wells and Eisenberg Regarding Article, "Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials"
    Wells, Martin T.
    Eisenberg, Theodore
    CIRCULATION, 2010, 122 (23) : E575 - E575
  • [3] Response to Letters Regarding Article, "Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women from Primary Prevention Trials"
    Mora, Samia
    Glynn, Robert J.
    MacFadyen, Jean G.
    Ridker, Paul M.
    Hsia, Judith
    Genest, Jacques
    CIRCULATION, 2010, 122 (23) : E577 - E577
  • [4] Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
    Everett, Brendan M.
    Glynn, Robert J.
    MacFadyen, Jean G.
    Ridker, Paul M.
    CIRCULATION, 2010, 121 (01) : 143 - 150
  • [5] Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)
    Ridker, Paul M.
    MacFadyen, Jean
    Libby, Peter
    Glynn, Robert J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (02): : 204 - 209
  • [6] Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER) - Can C-reactive protein be used to target statin therapy in primary prevention?
    Mora, S
    Ridker, PM
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (2A): : 33A - 41A
  • [7] Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein A Secondary Analysis From the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) Trial
    Ridker, Paul M.
    MacFadyen, Jean
    Cressman, Michael
    Glynn, Robert J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (12) : 1266 - 1273
  • [8] Letter by Giral et al Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)"
    Giral, Philippe
    Simon, Dominique
    Chapman, M. John
    CIRCULATION, 2014, 130 (17) : E151 - E151
  • [9] Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk Implications of the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for "Intermediate Risk"
    Ridker, Paul M.
    MacFadyen, Jean G.
    Nordestgaard, Borge G.
    Koenig, Wolfgang
    Kastelein, John J. P.
    Genest, Jacques
    Glynn, Robert J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (05): : 447 - 452
  • [10] Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
    Ridker, Paul M.
    MacFadyen, Jean G.
    Fonseca, Francisco A. H.
    Genest, Jacques
    Gotto, Antonio M.
    Kastelein, John J. P.
    Koenig, Wolfgang
    Libby, Peter
    Lorenzatti, Alberto J.
    Nordestgaard, Borge G.
    Shepherd, James
    Willerson, James T.
    Glynn, Robert J.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (06): : 616 - 623
12